VERAXA Biotech Appoints Dr. Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA), a clinical-stage biotechnology company focused on developing next-generation antibody-based cancer therapies, has appointed Christoph Erkel, Ph.D., as its new chief scientific officer, effective immediately. Dr. Erkel, who previously served as the company’s vice president of research and development, will now lead the advancement of VERAXA’s proprietary BiTAC(R) platform technologies, which are designed to develop bispecific T-cell engagers and other innovative antibody formats for treating solid tumors. He succeeds Rick Austin, Ph.D., who will depart after a transition period. Dr. Erkel brings over two decades of experience in antibody therapeutics, antibody engineering, and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs centered on T-cell engagers. VERAXA stated that his expertise in managing multidisciplinary research programs will be instrumental in expanding the company’s oncology pipeline and advancing BiTAC(R) candidates toward clinical development.

VERAXA Biotech AG, founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), positions itself as a premier engine for discovering and developing next-generation antibody-based therapeutics. The company’s pipeline includes bispecific T-cell engagers, bispecific ADCs, and other innovative formats, all powered by transformative technologies guided by quality-by-design principles. The appointment of Dr. Erkel is expected to accelerate the progression of these candidates into clinical trials and beyond. The company’s focus on solid tumors is particularly significant, as these cancers represent a large unmet medical need, and BiTAC(R) technology aims to enhance the efficacy and safety of immunotherapies. For more details, the full press release is available at https://nnw.fm/cR1RS.

The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. VERAXA Biotech’s forward-looking statements highlight the risks and uncertainties inherent in drug development, but the appointment of a seasoned CSO like Dr. Erkel signals a strategic push to bring innovative cancer therapies to patients. This leadership change underscores the company’s commitment to advancing its BiTAC(R) platform and addressing the challenges of solid tumor treatment, which remains a critical area in oncology research.